Mathew P Martin

发表

Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors

S. Olesen, A. Becker, E. Schönbrunn, 2014, ACS chemical biology.

Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.

S. Olesen, E. Schönbrunn, G. Georg, 2017, Journal of medicinal chemistry.

RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.

Ying Sun, E. Schönbrunn, S. Sebti, 2012, Cancer research.

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines

M. Noble, J. Endicott, I. Hardcastle, 2016, Journal of medicinal chemistry.

A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A.

E. Schönbrunn, S. Sebti, Riazul Alam, 2012, ACS chemical biology.

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor

Nathan Brown, Julian Blagg, Paul Workman, 2018, Molecular oncology.

Structure-based discovery and development of cyclin-dependent protein kinase inhibitors

M. Noble, J. Endicott, Mathew P. Martin, 2018 .

Structure-based discovery of cyclin-dependent protein kinase inhibitors.

M. Noble, J. Endicott, Mathew P Martin, 2017, Essays in biochemistry.

Molecular profiling and combinatorial activity of CCT068127

M. Noble, P. Workman, S. Whittaker, 2017 .

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure−Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substitued 2-Arylaminopurines

M. Noble, J. Endicott, I. Hardcastle, 2017 .

Identification and characterization of an irreversible inhibitor of CDK 2

M. Noble, J. Endicott, D. Staunton, 2017 .

Identification and Characterization of an Irreversible Inhibitor of CDK2

M. Noble, J. Endicott, D. Staunton, 2015, Chemistry & biology.

CDK1 structures reveal conserved and unique features of the essential cell cycle CDK

Jane A. Endicott, N. Brown, M. Noble, 2015, Nature Communications.

Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition

M. Noble, J. Endicott, Lan Z. Wang, 2019, Cell chemical biology.

Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains.

S. Olesen, E. Schönbrunn, Mathew P. Martin, 2013, ACS chemical biology.

Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.

A. Becker, C. Cubitt, Huijong Han, 2013, Journal of medicinal chemistry.

Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors

Mathew P. Martin, M. Guha, Wenyue Hu, 2022, International journal of toxicology.

A Novel Approach to the Discovery of Small‐Molecule Ligands of CDK2

E. Schönbrunn, Mathew P. Martin, S. Betzi, 2012, Chembiochem : a European journal of chemical biology.

Discovery of a potential allosteric ligand binding site in CDK2.

Huijong Han, E. Schönbrunn, Mathew P. Martin, 2011, ACS chemical biology.

Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2).

W. Guida, E. Schönbrunn, S. Sebti, 2012, MedChemComm.

Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors.

W. Guida, Yan Liu, S. Sebti, 2012, Journal of medicinal chemistry.

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

James D. Firth, Hanna F. Klein, M. Noble, 2020, Nature Communications.

Comparison of Quantitative Mass Spectrometric Methods for Drug Target Identification by Thermal Proteome Profiling

Amy L. George, J. L. Marín-Rubio, F. Sidgwick, 2023, Journal of proteome research.

A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia

J. Allan, O. Heidenreich, M. Trost, 2022, Journal of medicinal chemistry.

An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase.

M. Noble, J. Endicott, M. Waring, 2021, Journal of medicinal chemistry.

Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor

M. Noble, J. Endicott, S. Cook, 2022, Journal of medicinal chemistry.

Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.

M. Noble, J. Endicott, S. Cook, 2019, European journal of medicinal chemistry.

Differences in the Conformational Energy Landscape of CDK 1 andCDK 2 Suggest aMechanism for Achieving Selective CDK Inhibition Graphical

M. Noble, J. Endicott, Lan Z. Wang, 2018 .

Discovery of Diverse Small‐Molecule Inhibitors of Mammalian Sterile20‐like Kinase 3 (MST3)

S. Olesen, E. Schönbrunn, Jin-Yi Zhu, 2016, ChemMedChem.

Stability of the Human Hsp90-p50Cdc37 Chaperone Complex against Nucleotides and Hsp90 Inhibitors, and the Influence of Phosphorylation by Casein Kinase 2

S. Olesen, E. Schönbrunn, Mathew P. Martin, 2015, Molecules.

Mapping Ligand Interactions of Bromodomains BRD4 and ATAD2 with FragLites and PepLites—Halogenated Probes of Druglike and Peptide-like Molecular Interactions

M. Noble, J. Endicott, I. Hardcastle, 2022, Journal of medicinal chemistry.

Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8ob00099a

M. Noble, J. Endicott, I. Hardcastle, 2018, Organic & biomolecular chemistry.

FragLites-Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit Generation.

M. Noble, J. Endicott, M. Waring, 2019, Journal of medicinal chemistry.

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines

M. Noble, J. Endicott, I. Hardcastle, 2016, Journal of medicinal chemistry.

Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.

A. Becker, C. Cubitt, Huijong Han, 2013, Journal of medicinal chemistry.

Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy.

S. Wedge, Duncan C Miller, S. Harnor, 2023, Journal of medicinal chemistry.

RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.

Ying Sun, E. Schönbrunn, S. Sebti, 2012, Cancer research.

Conformational study into N-alkyl-N'-aryl ureas to inform drug discovery.

P. Waddell, Corinne Wills, M. Bon, 2023, Bioorganic & medicinal chemistry.

Build–Couple–Transform: A Paradigm for Lead-like Library Synthesis with Scaffold Diversity

M. Noble, B. Golding, Mathew P. Martin, 2022, Journal of medicinal chemistry.